Abstract
Antisense and small interfering RNA (siRNA) oligonucleotides have been recognized as powerful therapeutic compounds for targeting mRNAs and inducing their degradation. However, a major obstacle is that unmodified oligonucleotides are not readily taken up into tissues and are susceptible to degradation by nucleases. For these reasons, the design and preparation of modified DNA/RNA derivatives with better stability and an ability to be produced at large scale with enhanced uptake properties is of vital importance to improve current limitations. In the present study, we review the conjugation of oligonucleotides with lipids and peptides in order to produce oligonucleotide conjugates for therapeutics aiming to develop novel compounds with favorable pharmacokinetics.
Funder
Spanish Ministerio de Ciencia e Innovación
7th Framework Programme
VI National R + D + I Plan, Iniciativa Ingenio, Consolider Program
Reference225 articles.
1. A Randomized Controlled Clinical Trial of Intravitreous Fomivirsen for Treatment of Newly Diagnosed Peripheral Cytomegalovirus Retinitis in Patients with AIDS;Belfort;Am. J. Ophthalmol.,2002
2. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy;Finkel;N. Engl. J. Med.,2017
3. Eteplirsen Treatment for Duchenne Muscular Dystrophy: Exon Skipping and Dystrophin Production;Charleston;Neurology,2018
4. Therapeutic SiRNA: State of the Art;Hu;Signal. Transduct. Target. Ther.,2020
5. Antisense Technology: A Review;Crooke;J. Biol. Chem.,2021
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献